Wedbush Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$690K Buy
4,405
+82
+2% +$12.3K 0.02% 605
2026
Q1
$660K Sell
4,323
-811
-16% -$124K 0.02% 593
2025
Q4
$708K Buy
5,134
+260
+5% +$34K 0.02% 563
2025
Q3
$625K Buy
4,874
+1,179
+32% +$144K 0.02% 577
2025
Q2
$447K Buy
3,695
+333
+10% +$37.5K 0.02% 678
2025
Q1
$375K Buy
3,362
+139
+4% +$14.8K 0.01% 714
2024
Q4
$314K Sell
3,223
-433
-12% -$46.2K 0.01% 798
2024
Q3
$421K Sell
3,656
-5,847
-62% -$663K 0.02% 672
2024
Q2
$1.01M Sell
9,503
-2,052
-18% -$206K 0.04% 373
2024
Q1
$1.12M Buy
11,555
+5,655
+96% +$580K 0.04% 348
2023
Q4
$596K Sell
5,900
-110
-2% -$10.6K 0.03% 496
2023
Q3
$612K Sell
6,010
-946
-14% -$96K 0.03% 451
2023
Q2
$702K Sell
6,956
-363
-5% -$36.3K 0.03% 432
2023
Q1
$673K Buy
7,319
+453
+7% +$39.6K 0.03% 444
2022
Q4
$623K Sell
6,866
-120
-2% -$10.1K 0.03% 445
2022
Q3
$531K Sell
6,986
-4,964
-42% -$411K 0.03% 495
2022
Q2
$1.01M Buy
11,950
+179
+2% +$15.7K 0.06% 285
2022
Q1
$1.03M Sell
11,771
-604
-5% -$52.3K 0.05% 332
2021
Q4
$1.08M Sell
12,375
-1,886
-13% -$157K 0.05% 352
2021
Q3
$1.17M Buy
14,261
+15
+0.1% +$1.35K 0.06% 317
2021
Q2
$1.3M Sell
14,246
-605
-4% -$53.9K 0.06% 297
2021
Q1
$1.27M Buy
14,851
+2,061
+16% +$185K 0.07% 268
2020
Q4
$1.21M Sell
12,790
-707
-5% -$61.8K 0.11% 203
2020
Q3
$1.17M Sell
13,497
-1,180
-8% -$102K 0.11% 197
2020
Q2
$1.28M Sell
14,677
-2,441
-14% -$211K 0.12% 170
2020
Q1
$1.41M Sell
17,118
-1,539
-8% -$137K 0.17% 126
2019
Q4
$1.77M Buy
18,657
+205
+1% +$18.4K 0.16% 148
2019
Q3
$1.6M Buy
18,452
+497
+3% +$44.6K 0.16% 150
2019
Q2
$1.64M Sell
17,955
-632
-3% -$53.5K 0.16% 148
2019
Q1
$1.6M Buy
18,587
+538
+3% +$43.2K 0.17% 138
2018
Q4
$1.39M Sell
18,049
-1,547
-8% -$120K 0.18% 134
2018
Q3
$1.51M Sell
19,596
-914
-4% -$67.6K 0.17% 129
2018
Q2
$1.39M Sell
20,510
-1,993
-9% -$138K 0.17% 137
2018
Q1
$1.63M Sell
22,503
-584
-3% -$44.5K 0.21% 111
2017
Q4
$1.74M Buy
23,087
+609
+3% +$46K 0.21% 105
2017
Q3
$1.73M Buy
22,478
+950
+4% +$71.7K 0.22% 88
2017
Q2
$1.61M Sell
21,528
-2,434
-10% -$173K 0.21% 102
2017
Q1
$1.59M Buy
23,962
+623
+3% +$41.5K 0.22% 94
2016
Q4
$1.52M Sell
23,339
-201
-0.9% -$13K 0.22% 85
2016
Q3
$1.67M Buy
23,540
+1,290
+6% +$94K 0.25% 78
2016
Q2
$1.65M Buy
22,250
+8,650
+64% +$598K 0.27% 75
2016
Q1
$883K Buy
13,600
+1,183
+10% +$80.5K 0.15% 146
2015
Q4
$957K Sell
12,417
-264
-2% -$21K 0.17% 126
2015
Q3
$1.04M Buy
12,681
+222
+2% +$19.8K 0.21% 111
2015
Q2
$1.1M Buy
12,459
+723
+6% +$66.3K 0.2% 110
2015
Q1
$1.04M Buy
11,736
+1,000
+9% +$88.7K 0.18% 126
2014
Q4
$891K Buy
10,736
+690
+7% +$57.2K 0.14% 147
2014
Q3
$847K Buy
10,046
+599
+6% +$48.5K 0.13% 155
2014
Q2
$766K Buy
9,447
+728
+8% +$57.3K 0.12% 176
2014
Q1
$664K Buy
8,719
+1,875
+27% +$137K 0.12% 185
2013
Q4
$493K Sell
6,844
-452
-6% -$31.4K 0.12% 206
2013
Q3
$501K Buy
7,296
+460
+7% +$30.4K 0.13% 184
2013
Q2
$433K Buy
+6,836
New +$445K 0.12% 211

Other funds holding NVS

Wedbush Securities's NVS Position: Q2 2026 in Review

Wedbush Securities increased its Novartis (NVS) stake by 1.9% in Q2 2026, buying an estimated $12.3K and bringing the position to 4,405 shares worth $690K. The position accounts for 0.02% of the portfolio, ranked #605.

Wedbush Securities first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.77M in Q4 2019. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Wedbush Securities held 4,405 shares of Novartis worth $690K as of Q2 2026.
  • Wedbush Securities bought 82 Novartis shares in Q2 2026, an estimated $12.3K.
  • Novartis made up 0.02% of Wedbush Securities's portfolio in Q2 2026, its #605 holding.
  • Wedbush Securities first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Wedbush Securities's Novartis position peaked at $1.77M in Q4 2019.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.